To compare the anatomical and functional outcomes in patients with macular edema due to central retinal vein occlusion treated with Ranibizumab or Aflibercept

Trial Profile

To compare the anatomical and functional outcomes in patients with macular edema due to central retinal vein occlusion treated with Ranibizumab or Aflibercept

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Retinal oedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top